Oxurion NV — Director's Dealing 2023

Apr 24, 2023

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

April 24, 2023

Regulated Information

Leuven, BELGIUM, Boston, MA, US – April 24, 2023 – 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:

Oxurion received a transparency notification on April 14, 2023, from Atlas Special Opportunities LLC indicating that as of March 23, 2023, it held 11,055,598 shares of the then outstanding 603,716,557 shares, and therefore crossed below the threshold (3%) by virtue of sale of voting securities. See Annex 1.

Oxurion received a transparency notification on April 19, 2023, from Atlas Special Opportunities LLC indicating that as of March 30, 2023, it held 7,055,741 shares of the then outstanding 632,659,186 shares, and therefore crossed below the threshold (3%) by virtue of sale of voting securities. See Annex 2.

Oxurion received a transparency notification on April 14, 2023, from Atlas Special Opportunities LLC indicating that as of April 12, 2023, it held 15,407,185 shares of the then outstanding 659,387,625 shares, and therefore crossed below the threshold (3%) by virtue of sale of voting securities. See Annex 3.

In addition, on April 14, 2021, Oxurion announced the receipt on April 12, 2023, of a transparency notification from Atlas Special Opportunities LLC indicating that as of April 11, 2023, Atlas held 26,728,439 shares of the then outstanding 632,659,186 shares and therefore had crossed above the threshold (3%) by virtue of the acquisition of voting securities. The correct transaction date for this notice was however April 5, 2023. See Annex 4.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Tom Graney	US Conway Communications
Chief Executive Officer	Mary T. Conway
Tel: +32 16 75 13 10	mtconway@conwaycommsir.com
" tom.graney@oxurion.com
	ICR Westwicke Christopher Brinzey
Michael Dillen	Tel: +1 617 835 9304
Chief Business Officer	Chris.Brinzey@westwicke.com
Tel: +32 16 75 13 10
michael.dillen@oxurion.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

________

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer
	Name OXURION Identification number 0881-620-924
3) Reason for the notification
	Downward crossing of the lowest threshold
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name Atlas Special Opportunities LLC	Address (for legal entities) 2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name	Address (for legal entities)
	D persons referred to in Sections 5 and 6	Please continue entering the information in part II concerning the Part II
7) Date on which the threshold is crossed
23/03/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
3
		If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

603,716,557 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights % of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC		11,055,598		1.83%
	TOTAL	11,055,598		1.83%

Start with "groups" of holders. Add subtotals with 21, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or leg

ıcuSign Envelope ID: 5ACB4DC9-94CD-4E31-A36F-77D195306A48

L

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
	TOTAL

The totals will be updated once you have clicked on

OTAL (A & B)		# of voting rights % of voting rights
	CALCULATE 11,055,598	1.83%

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder	will cease to hold / will hold again	(DD/MM/YYYY) voting rights as of
13) Additional information
On 22/03/2023, Atlas Special Opportunities LLC acquired 19,013,817 shares in Oxurion NV.

	Done at New York
On	11/04/2023	(DD/MMYYYY)
	Name & capacity Patrick Vance, proxyholder

- Decedigned by Signature Patnek Vance
-523422378265440

ANNEX 2

SMA FINANCIAL SERVICES AND MARKETS AUTHORITY		Transparency notification Form TR-1 BE PART I
1) Status of the notification
Final
2) Issuer
Name OXURION
Identification number 0881-620-924
3) Reason for the notification
	Downward crossing of the lowest threshold
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name	Address (for legal entities)
	Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name	Address (for legal entities)
P	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
		30/03/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		3
		If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

632,659,186 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	11,055,598	7,055,741	0	1.12%	0.00%
	TOTAL	7,055,741		1.12%

+

Start with "groups" of holders. Add subtotals with 2, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or le

uSign Envelope ID: E351CCC3-143D-4DA4-902E-6FDE34E11348

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
	TOTAL

The totals will be updated once you have clicked on

TOTAL (A & B)		# of voting rights % of voting rights
	CALCULATE	7,055,741	1.12%

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder	will cease to hold / 0 will hold again	(DD/MM/YYYY) voting rights as of
13) Additional information
On 28/03/2023, Atlas Special Opportunities LLC acquired 28,942,629 shares in Oxurion NV.

	Done at New York
On		12/04/2023 (DD/MMYYYYY)
	Name & capacity Patrick Vance, proxyholder

	16 1 11 11 11 4 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 Signature Patrick Varie
	-5534B237B29544C

ANNEX 3

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY		Transparency notification Form TR-1 BE PART I
1) Status of the notification
Final
2) Issuer
Name OXURION Identification number 0881-620-924
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
	Downward crossing of the lowest threshold
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name	Address (for legal entitles)
	Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name	Address (for legal entities)
S	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
12/04/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
3
		If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	26.728.439	15,407,185	O	2.34%	0.00%
TOTAL		15,407,185		2.34%

Start with "groups" of holders. Add subtotals with 2, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or leg

+

cuSign Envelope ID: 5C26C860-4988-49C9-8F84-2A5350A142D0

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial Instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the Instrument is exercised	% of voting rights	Settlement
							+
	TOTAL

The totals will be updated once you have clicked on

TOTAL (A & B)		# of voting rights % of voting rights
	CALCULATE	15,407,185	2.34%

12) In case of proxy voting for only one GM

			(DD/MM/YYYY)
Holder	will cease to hold / will hold again	voting rights as of

13) Additional information

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	Done at New York
Ôn		13/04/2023 (DD/MM/YYYY)
	Name & capacity Patrick Vance, proxyholder	Signature	- Duest deglion 1577 Patrick Vance - 553492378295440

ANNEX 4

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
Final 2) Issuer
Name OXURION ldentification number 0881-620-924
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights
4) Notification by
A person that notifies alone
5) Persons subject to the notification requirement
Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name	Address (for legal entities)
D persons referred to in Sections 5 and 6	Please continue entering the information in part II concerning the Part II
7) Date on which the threshold is crossed
	05/04/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
3
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	7.055.741	26,728,439	0	4.22%	0.00%
TOTAL		26,728,439	0	4.22%	0.00%

+

Start with "groups" of holders. Add subtotals with Z, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or l

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
TOTAL				0	0.00%

P	The totals will be updated once you have clicked on
	TOTAL (A & B)			# of voting rights % of voting rights
		CALCULATE	26,728,439	4.22%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

12) In case of proxy voting for only one GM

			(DD/MM/YYYY)
Holder	will cease to hold / will hold again	voting rights as of

13) Additional information

	Done at New York
On		11/04/2024 (DD/MM/YYYY)
	Name & capacity Patrick Vance, proxyholder

-Docu Signed by: Signature Patrick Vance
- 553482978266440

Attachments

• EN
• NL